<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40436210</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Complementary therapies in medicine</Title><ISOAbbreviation>Complement Ther Med</ISOAbbreviation></Journal><ArticleTitle>The efficacy of moxibustion on the pressure pain threshold and substance P / leukotriene B4 contents in serum to patients with rheumatoid arthritis.</ArticleTitle><Pagination><StartPage>103187</StartPage><MedlinePgn>103187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctim.2025.103187</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0965-2299(25)00062-7</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To observe the effects of moxibustion on pressure-pain thresholds (PPTs) in affected joints and non-joint areas, as well as the contents of substance P (SP) and leukotriene B4 (LTB4) in serum of patients with rheumatoid arthritis (RA), and to explore the analgesic mechanism of moxibustion in RA patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 72 patients with RA were randomly and equally classified into the control and treatment groups. The control group was treated with routine drug therapy, while the treatment group received routine drug therapy and moxibustion. Both groups were treated for 8 weeks. The symptoms, measured by PPTs, Visual analogue scale (VAS), pain joint count (PJC), swollen joint count (SJC) and disease activity score of 28 joints (DAS28), and laboratory indicators, measured by the level of SP, LTB4, tumor necrosis factor- &#x3b1; (TNF-&#x3b1;) and interleukin-1&#x3b2; (IL-1&#x3b2;), were compared in the two groups before and after intervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 66 patients completed the trial, with 1 patients dropping out from the treatment group and 5 patients being excluded and dropped from the control group. Trial endpoints were change (&#x2206;) in symptoms and laboratory indicators. The treatment group showed superior in &#x2206;PPTs of the interphalangeal joints(1301.71 (95&#x202f;%CI, 967.43-1636.00) vs 443.23(95&#x202f;%CI, 99.51-786.95)), &#x2206;SP(10.11 (95&#x202f;%CI, 5.85-14.37) vs 3.10 (95&#x202f;%CI, -1.13-7.34)), &#x2206; LTB4(13.17 (95&#x202f;%CI, 7.81-18.54) vs 3.37 (95&#x202f;%CI, -5.73-12.48)), &#x2206;TNF-&#x3b1;(4.57 (95&#x202f;%CI, 2.60-6.55) vs 0.68 (95&#x202f;%CI, -1.03-2.40)), &#x2206;IL-1&#x3b2;(4.63 (95&#x202f;%CI, 2.59-6.66) vs 1.63 (95&#x202f;%CI, -0.53-3.80)), &#x2206;PJC(7.14 (95&#x202f;%CI, 5.17-8.58) vs 1.84 (95&#x202f;%CI, 0.66-3.02)), &#x2206;SJC(5.20 (95&#x202f;%CI, 3.44-6.96) vs 1.00(95&#x202f;%CI, 0.02-1.98)), &#x2206;VAS(3.6 (95&#x202f;%CI, 2.99-4.21) vs 0.9 (95&#x202f;%CI, 0.24-1.57)), and &#x2206;DAS(1.68 (95&#x202f;%CI, 1.44-1.92) vs 0.41 (95&#x202f;%CI, 0.08-0.73)) compared to the control group, at weeks 4. Furthermore, there was a significant negative correlation between &#x2206;PPTs of the interphalangeal joints and &#x2206;SP in the treatment group (r&#x202f;&lt;&#x202f;0, P&#x202f;&lt;&#x202f;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Moxibustion combined with conventional western medicine can significantly improve PPTs in affected joints of RA patients, alleviate clinical symptoms, and reduce disease activity. The potential mechanism may be related to the down-regulation of SP and LTB4 levels and the reduction of the release of inflammatory factors Il-1&#x3b2; and TNF-&#x3b1; by moxibustion. The lack of double-blinding is a limitation of our study, which we plan to avoid by establishing a sham moxibustion group in the subsequent trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Siyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Nannan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Chengdu, Sichuan province 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China. Electronic address: wuping_33@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>Complement Ther Med</MedlineTA><NlmUniqueID>9308777</NlmUniqueID><ISSNLinking>0965-2299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1HGW4DR56D</RegistryNumber><NameOfSubstance UI="D007975">Leukotriene B4</NameOfSubstance></Chemical><Chemical><RegistryNumber>33507-63-0</RegistryNumber><NameOfSubstance UI="D013373">Substance P</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009071" MajorTopicYN="Y">Moxibustion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007975" MajorTopicYN="Y">Leukotriene B4</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013373" MajorTopicYN="Y">Substance P</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017288" MajorTopicYN="Y">Pain Threshold</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ChiCTR-IOR-17012282</Keyword><Keyword MajorTopicYN="N">Interleukin-1&#x3b2;</Keyword><Keyword MajorTopicYN="N">Leukotriene B4</Keyword><Keyword MajorTopicYN="N">Moxibustion</Keyword><Keyword MajorTopicYN="N">Pressure pain threshold</Keyword><Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">Substance P</Keyword><Keyword MajorTopicYN="N">Trial registration number</Keyword><Keyword MajorTopicYN="N">Tumor necrosis factor-&#x3b1;</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest I, Siyu Tao, declare that there are no conflicts of interest in relation to the manuscript titled " The Efficacy of Moxibustion on the Pressure Pain Threshold and substance P / leukotriene B4 Contents in Serum to Patients with Rheumatoid Arthritis " submitted to Complementary Therapies in Medicine. I confirm that the results and interpretations reported in the manuscript are original and have not been plagiarized. I certify that I have read and understand the Complementary Therapies in Medicine conflict of interest policy, and I understand that failure to disclose a conflict of interest may result in the manuscript being rejected or retracted. I also certify that I have disclosed any financial or non-financial relationships that may be interpreted as constituting a conflict of interest in relation to this manuscript. I understand that this information will be subject to peer review, and I am willing to provide further information or clarification if required. I confirm that I have no known conflicts of interest that would influence the results or interpretation of the data presented in this manuscript, and I understand that failure to disclose a conflict of interest is unethical and may result in sanctions being imposed on me.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>29</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>19</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40436210</ArticleId><ArticleId IdType="doi">10.1016/j.ctim.2025.103187</ArticleId><ArticleId IdType="pii">S0965-2299(25)00062-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>